The FLT3 gene in humans encodes the protein FLT3, also known as Fms-like tyrosine kinase 3 (CD135). The class III receptor tyrosine kinase family includes FLT3, a cytokine receptor.FLT3 is the cytokine Flt3 ligand (FLT3L)'sreceptor. On the surface of many hematopoietic progenitor cells, FLT-3 is expressed. The normal development of hemopoietic stem cells and progenitor cells depends on FLT3 signaling. One of the genes with the highest frequency of mutations in acute myeloid leukemia (AML) is FLT3. Furthermore, high FLT3 levels in blast cells from some AML patients without FLT3 mutations have been observed. The prognosis may be worse when these levels are high. Cell proliferation, differentiation, and survival are influenced by FLT3 signaling. FLT3 is crucial for the growth of lymphocytes (B and T cells), but not for the growth of other blood cells. The cytokines TNF-Alpha and TGF-Beta both inhibit FLT3 activity.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V128319 | Adezkibart | 2921564-55-6 | Adezkibart is a human monoclonal antibody immunosuppressant that targets human FMS-like tyrosine kinase 3 ligand (FLT3LG). |
|
V129966 | BDT001 | 823837-22-5 | BDT001 is a selective FLT3 receptor antagonist that can be used in research on pain disorders, cancer, and autoimmune diseases. |
|
V69488 | BPR1K871 (DBPR114) | 2443767-35-7 | BPR1K871 (DBPR114) is a potent and specific FLT3/AURKA dual (bifunctional) inhibitor (antagonist) with IC50s of 19 nM and 22 nM for FLT3 and AURKA respectively. |
|
V131474 | CHEMBL4444839 | 2316841-82-2 | CHEMBL4444839 is an FLT3 inhibitor that can be used in research on acute myeloid leukemia (AML). |
|
V88051 | D-65476 | 249762-74-1 | D-65476 is a type III receptor tyrosine kinase (Flt3) inhibitor. |
|
V69292 | Dovitinib lactate (CHIR-258 lactate; TKI-258 lactate) | 692737-80-7 | Dovitinib lactate (TKI258 lactate) is a multi-target tyrosine kinase inhibitor, inhibiting FLT3, c-Kit, FGFR1/3, VEGFR1/2/3 and PDGFRα/β with IC50s of 1, 2, 8/9 respectively. |
|
V69283 | Dovitinib-d8 (Dovitinib d8) | 1246819-84-0 | Dovitinib-d8 is the deuterated form of Dovitinib. |
|
V136094 | Flonoltinib monomaleate | Flonoltinib monomaleate is a potent and orally effective dual JAK2/FLT3 inhibitor with IC50 values of 0.7 nM, 4 nM, 26 nM, and 39 nM for JAK2, FLT3, JAK1, and JAK3, respectively. | |
|
V102949 | Flonoltinib sulfate | 2568842-57-7 | Flunotinib maleate is an oral dual JAK2/FLT3 inhibitor with IC50 of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. |
|
V117072 | Flt-3-IN-1 | Flt-3-IN-1 is a potent FLT-3 inhibitor with an IC50 value of 0.91 μM. | |
|
V118845 | FLT3 D835Y Recombinant Human Active Protein Kinase | FLT3 (FMS-like tyrosine kinase 3, CD135) is a type 3 receptor tyrosine kinase that plays a crucial role in cell survival, proliferation, and differentiation during normal hematopoiesis. | |
|
V118866 | FLT3 ITD Recombinant Human Active Protein Kinase | FLT3 (FMS-like tyrosine kinase 3, CD135) is a type 3 receptor tyrosine kinase that plays a crucial role in cell survival, proliferation, and differentiation during normal hematopoiesis. | |
|
V105277 | FLT3 Ligand-Linker Conjugate 1 | 2769753-49-1 | FLT3 ligand-adapter conjugate 1 contains the FLT3 ligand and a PROTAC adaptor that recruits the E3 ligase VHL. |
|
V69489 | FLT3-IN-10 | 2088735-51-5 | FLT3-IN-10 (compound 7c) is a potent inhibitor of FMS-like tyrosine kinase 3 (FLT3). |
|
V69500 | FLT3-IN-18 | 752191-77-8 | FLT3-IN-18 is a potent and specific FLT3 inhibitor (antagonist) with IC50 of 0.003 μM. |
|
V69492 | FLT3-IN-19 | 2237234-48-7 | FLT3-IN-19 (Comp 50) is a potent and specific FLT3 inhibitor (antagonist) with IC50 of 0.213 nM. |
|
V85849 | FLT3-IN-24 | ||
|
V85815 | FLT3-IN-25 | ||
|
V93273 | FLT3-IN-27 | FLT3-IN-27 (Compound 49) is a FLT3-ITD inhibitor with IC50 of 174 nM. | |
|
V105152 | FLT3-IN-28 | FLT3-IN-28 (compound 12y) is an orally available FLT3 inhibitor with antitumor activity. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
